Holen Sie sich die Stockscreener-App
1.34
3.96%
-0.05
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Humacyte (NASDAQ: HUMA) holders OK share boost, pay and auditor - Stock Titan
HUMA: All proposals, including director elections and share increase, passed with strong support - TradingView
HUMA Reiterates by BTIG -- Price Target Maintained at $2.00 - GuruFocus
Humacyte, Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Regulatory Disclosures - Minichart
Humacyte Regains Nasdaq Compliance With Minimum Bid Price - TipRanks
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Lelezard
Humacyte regains Nasdaq $1.00 bid-price compliance after May deficiency - TradingView
Humacyte (NASDAQ: HUMA) back in line with Nasdaq $1.00 bid rule - Stock Titan
HUMA Technical Analysis | Trend, Signals & Chart Patterns | HUMACYTE INC (NASDAQ:HUMA) - ChartMill
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
Benchmark raises Humacyte stock price target on dialysis launch hopes By Investing.com - Investing.com South Africa
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $2 - Moomoo
HUMA Maintained by Benchmark -- Price Target Raised to $2.00 - GuruFocus
Humacyte (HUMA) Q1 2025 Earnings Transcript - The Globe and Mail
Benchmark raises Humacyte stock price target on dialysis launch hopes - Investing.com
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis DataHas The Bull Case Changed? - Yahoo Finance
Humacyte (HUMA) Is Up 23.8% After New ATEV Self‑Repair Data And Phase 3 Timeline Update - Sahm
Humacyte, Inc. (HUMA) reports Q1 loss, misses revenue estimates - MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com Nigeria
Wall Street bulls look optimistic about Humacyte, Inc. (HUMA): Should you buy? - MSN
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? - Yahoo Finance
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Humacyte Inc. (HUMA) Gains 3.6% as Stock Approaches Key Resistance LevelMA Crossover - thelegaladvocate.com
HUMA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Humacyte Price Target Maintained With a $3.00/Share by HC Wainwright & Co. - Moomoo
Humacyte presents dialysis access vessel research at VASA meeting By Investing.com - Investing.com Nigeria
Humacyte presents dialysis access vessel research at VASA meeting - Investing.com
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - The Manila Times
Dialysis graft that self-repairs despite hundreds of needle sticks - Stock Titan
Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today? - MSN
HUMA Q1 2026 Earnings: Narrowing Losses Drive Positive Surprise as Stock Gains 11%Banking Earnings Report - thelegaladvocate.com
Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88 - Stock Titan
Humacyte (HUMA) director adds 11,000 shares at about $0.89 - Stock Titan
Humacyte (HUMA) CFO executes 45,887-share sell-to-cover trade for RSU taxes - Stock Titan
Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan - Stock Titan
Humacyte’s Symvess added to VA hospital contract system - Investing.com UK
Humacyte’s Symvess added to VA hospital contract system By Investing.com - Investing.com South Africa
VA hospitals to get easier access to Humacyte Symvess product - Stock Titan
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - Insider Monkey
[144] Humacyte, Inc. SEC Filing - Stock Titan
0.45%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):